UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K/A

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

March 27, 2023

Date of Report (Date of earliest event reported)

 

HUAIZHONG HEALTH GROUP INC.

(Exact Name of Registrant as Specified in Charter)

 

 

Nevada

 

001-55369

 

90-1020141

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

Tianan Technology Park, 13/F Headquarters Center Building 16, 555 Panyu North Ave, Panyu District, Guangzhou City, China 511493

(Address of Principal Executive Offices, and   Zip Code) 

 

+ 86 (20) 2982-9356

Registrant’s Telephone Number, Including Area Code

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock

 

ADAD

 

OTC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 1.02. Termination of a Material Definitive Agreement.

 

On July 17, 2023, Huaizhong Health Group Inc., (the “Company”), Sannong Youxuan (BVI) Limited (the “Target”), and Sannong Youxuan Holdings Limited, the sole shareholder of the Target (the “Seller”) entered into a Termination Agreement (the “Termination Agreement”), pursuant to which the Company and the Seller agreed to terminate the Share Exchange Agreement, entered into on March 27, 2023 (the “Share Exchange Agreement”). Effective as of the date of termination, the Seller, the Target and the Company, on their own behalf and on behalf of their affiliates and other related parties, mutually released the other party from any claims that may have been made by such party against the other party arising from or relating to the Share Exchange Agreement, including the performance thereof and further payment obligations of any kind in connection therewith.

 

The Termination Agreement is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The description of the Termination Agreement above does not purport to be complete and is qualified in its entirety by reference to the Termination Agreement.

 

 
2

 

 

 

Item 9.01 Financial Statement and Exhibits.

 

(d) Exhibits

 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

99.1

 

Termination Agreement, dated as of July 17, 2023, by and among Huaizhong Health Group Inc., Sannong Youxuan (BVI) Limited, and Sannong Youxuan Holdings Limited

 

 
3

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Report on Form 8-K/A to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

HUAIZHONG HEALTH GROUP INC.

 

 

 

 

 

Dated: July 17, 2023

By:

/s/ Yuantong Wang

 

 

Name:

Yuantong Wang

 

 

Title:

Chief Executive Officer and Chairman

 

 

 
4

 

nullv3.23.2
Cover
Mar. 27, 2023
Cover [Abstract]  
Entity Registrant Name HUAIZHONG HEALTH GROUP INC.
Entity Central Index Key 0001593204
Document Type 8-K/A
Amendment Flag true
Amendment Description None
Entity Emerging Growth Company false
Document Period End Date Mar. 27, 2023
Entity Incorporation State Country Code NV
Entity Tax Identification Number 90-1020141
Written Communications false
Soliciting Material false
Entity Address Address Line 1 Tianan Technology Park
Entity Address Address Line 2 13/F Headquarters Center Building 16
Entity Address Address Line 3 555 Panyu North Ave, Panyu District
Entity Address City Or Town Guangzhou City
Entity Address Postal Zip Code 511493
City Area Code 86 (20)
Local Phone Number 2982-9356
Trading Symbol ADAD
Entity File Number 001-55369
Entity Address Country CN
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Huaizhong Health (CE) (USOTC:ADAD)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Huaizhong Health (CE) Charts.
Huaizhong Health (CE) (USOTC:ADAD)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Huaizhong Health (CE) Charts.